TLX250-CDx
Clear Cell Renal Cell Carcinoma (ccRCC) Imaging
Key Facts
Indication
Clear Cell Renal Cell Carcinoma (ccRCC) Imaging
Phase
Phase 3
Status
NDA Submitted
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals is a global leader in radiopharmaceuticals, focusing on theranostics—a combined diagnostic and therapeutic approach for cancer. The company has achieved commercial success with its FDA-approved prostate cancer imaging agent, Illuccix®, and is advancing a deep clinical pipeline targeting renal, brain, and other cancers. With a vertically integrated platform spanning discovery to commercialization, Telix is strategically positioned to capture significant value in the high-growth precision oncology market.
View full company profile